Compounds > farglitazar
Page last updated: 2024-09-05

farglitazar and Alloxan Diabetes

farglitazar has been researched along with Alloxan Diabetes in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM1
Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ1
Ayscue, AH; Henke, BR; Lambert, MH; Leesnitzer, LM; Liu, KG; Oliver, WR; Plunket, KD; Sternbach, DD; Willson, TM; Xu, HE1
Carrick, KM; Clifton, LG; Lin, P; McNulty, JA; Pahel, GL; Stimpson, SA; Strum, JC; Winegar, DA; Yang, B1

Other Studies

4 other study(ies) available for farglitazar and Alloxan Diabetes

ArticleYear
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
    Journal of medicinal chemistry, 1998, Dec-03, Volume: 41, Issue:25

    Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine

1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Journal of medicinal chemistry, 1998, Dec-03, Volume: 41, Issue:25

    Topics: Administration, Oral; Animals; Benzoates; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; ortho-Aminobenzoates; Oxazoles; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Solubility; Structure-Activity Relationship; Transcription Factors; Tyrosine

1998
Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.
    Bioorganic & medicinal chemistry letters, 2001, Dec-17, Volume: 11, Issue:24

    Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Molecular Weight; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tyrosine

2001
PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats.
    Biochemical and biophysical research communications, 2005, Aug-19, Volume: 334, Issue:1

    Topics: 3T3-L1 Cells; Adipocytes; Animals; Diabetes Mellitus, Experimental; Diet; Dose-Response Relationship, Drug; Insulin; Insulin Resistance; Male; Mice; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Tyrosine; Vascular Endothelial Growth Factor A

2005